Ductal carcinoma in situ

From Citizendium
Jump to navigation Jump to search
This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In oncology, ductal carcinoma in situ (DCIS), also called noninfiltrating intraductal carcinoma, is "a noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma."[1]

The importance of DCIS is not clear..[2] However, it may benefit from treatment.[3]

References

  1. Anonymous (2024), Ductal carcinoma in situ (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G et al. (2009). "Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.". Ann Intern Med 151 (10): 738-47. DOI:10.1059/0003-4819-151-10-200911170-00010. PMID 19920274. Research Blogging.
  3. Cuzick, Jack; Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George (2010). "Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial". The Lancet Oncology. DOI:10.1016/S1470-2045(10)70266-7. ISSN 14702045. Retrieved on 2010-12-08. Research Blogging.